| P-gp1 | p53 mutation2 | Endothelial cell growth (%)3 | Endothelial cell survival (%)4 |
---|---|---|---|---|
Positive control5 |  |  | 100 ± 8 | 100 ± 9 |
Negative control6 |  |  | 5 ± 7 | 12 ± 6 |
UKF-NB-3 | - | - | 15 ± 6 | 22 ± 8 |
UKF-NB-3rVCR10 | + | + (C135F) | 78 ± 12* | 83 ± 12* |
UKF-NB-3rCDDP1000 | - | - | 89 ± 9* | 85 ± 7* |
UKF-NB-3rDOX20 | + | - | 66 ± 13* | 70 ± 6* |
UKF-NB-2 | - | - | 17 ± 11 | 20 ± 5 |
UKF-NB-2rVCR10 | + | - | 48 ± 13* | 55 ± 8* |
UKF-NB-2rCDDP1000 | - | - | 38 ± 7* | 48 ± 10* |
UKF-NB-2rDOX20 | + | - | 35 ± 9* | 42 ± 9* |
IMR-32 | - | - | 8 ± 6 | 17 ± 5 |
IMR-32rVCR10 | + | - | 63 ± 15* | 67 ± 8* |
IMR-32rCDDP1000 | - | - | 49 ± 7* | 58 ± 6* |
IMR-32rDOX20 | - | - | 37 ± 8* | 44 ± 14* |
UKF-NB-4 | + | + (C175F) | 92 ± 9# | 78 ± 15# |
Be(2)-C | + | + (C135F) | 94 ± 16# | 90 ± 7# |